普洛药业(000739.SZ)：头孢地尼胶囊获得药品注册证书

Core Viewpoint - Pro Pharmaceutical Co., Ltd. has received a drug registration certificate for Cefdinir capsules from the National Medical Products Administration, indicating a significant regulatory milestone for the company [1] Group 1: Company Developments - The subsidiary Zhejiang Pro Kangyu Pharmaceutical Co., Ltd. is responsible for the newly approved Cefdinir capsules [1] - Cefdinir is indicated for various infections caused by sensitive strains of bacteria, including Streptococcus, Staphylococcus, and Escherichia coli, among others [1] Group 2: Product Indications - The approved indications for Cefdinir capsules include infections such as pharyngitis, tonsillitis, acute bronchitis, pneumonia, otitis media, sinusitis, pyelonephritis, cystitis, and gonococcal urethritis [1] - Additional indications cover conditions like pelvic inflammatory disease, intrauterine infections, and various skin and soft tissue infections [1]